Navigation Links
Lytix Presents LTX-109 Anti-Microbial Data at ICAAC
Date:11/20/2008

TROMSO, Norway, November 20 /PRNewswire/ -- The Scandinavian-based drug development company Lytix Biopharma has announced results of studies on its lead antimicrobial candidate LTX-109. Presented at ICAAC in Washington, DC, the studies showed that the novel lytic peptidomimetic has an ultra-rapid bacteriocidal effect, significantly better towards killing Staphylococcus aureus and Streptococcus pyogenes than marketed gold standard drugs. In addition to this it has proven effective against a wide range of 110 European Pseudomonas aeruginosa clinical isolates, a problrmatic Gram (-) bacterium.

According to Lytix Biopharma spokesperson Anders Fugelli, these are important studies: "The fact that LTX-109 is effective against a broad range of pathogens highlights its potential utility as a truly novel broad spectrum antimicrobial drug. Indeed it is so effective, that although the initial formulation is for the treatment of skin infections, we could now consider it for other indications such as skin and nail fungal infections, acne and oropharyngeal candidaisis. We are now in the final stages of preclinical development and look forward to taking LtX-109 into the clinic in during the second half of 2009."

LTX-109 is a novel synthetic antimicrobial pepitidomimetic (SAMP) drug with a rapid bactericidal mode of action that can effectively synthesized in scalable, low-cost chemical reactor systems.

About Lytix Biopharma AS

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments. Lytix was established in 2003 to commercialise world-class research in the field of lytic peptides spun out by the founding scientists working in the University Hospital and University of Tromso in Norway.

Operating out of a main office located in Tromso and through our continued collaboration with the University of Tromso the Company has access to state-of-the-art laboratories and staff with extensive experience of developing peptide based drugs, including preparation of peptidomimetics. Business and product development is driven from the subsidiary office in Oslo.

   http://www.lytixbiopharma.com

    Corporate Inquiries:

    Anders Fugelli
    Head of Business Development
    Lytix Biopharma AS
    P.O. Box 6447, Tromso Research Park
    N-9294 Tromso, Norway

    Tel +47-924-81-432
    Email: anders.fugelli@lytixbiopharma.com


'/>"/>
SOURCE Lytix Biopharma AS
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
5. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
6. Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
7. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
8. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
9. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
10. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
11. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants totaling ... as part of its prestigious Bayer Hemophilia Awards Program (BHAP). ... Philadelphia and Uniformed Services University of ... among the winners. Grant recipients were announced last night during ... (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/10/2017)... medical equipment and supply demand is forecast to reach ... Equipment & Supplies: United States , a report ... demand for medical services – driven in large part ... gains in disposable personal income – will boost sales ... also drive sales as providers and patients seek the ...
(Date:7/6/2017)... 2017 ThriveRx, the nutrition division of Diplomat Specialty Infusion Group, ... on nutrition support. To celebrate its anniversary, ThriveRx recently launched ... fresh new look with improved organization to create the best user experience ... ... "We,ve made several great ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... ... The Margarian Law Firm has filed a class action lawsuit against Dr. ... ginger. Dr. Pepper produces the “Canada Dry” brand of ginger ale products. In Gegham ... Ale claims on its bottle that it is made from real ginger. , When ...
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has launched ... of acceptance to a residency in a United States hospital. Being accepted into ... U.S. , According to data released by the ECFMG®, every year, 50 percent ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased to announce ... Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network of medical ... dermatology, skin cancer , and more. She graduated from the University of Florida ...
(Date:7/21/2017)... ... 21, 2017 , ... How physicians and athletic trainers assess ... researchers presenting their work at the American Orthopaedic Society for Sports Medicine’s ... the patterns of change in concussion symptom presentation, diagnostic tools used and length ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) ... progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a ... relapse. With such a challenging diagnosis that requires immediate action, patients and ...
Breaking Medicine News(10 mins):